Orthocell Ltd has released a press release.
Remplir Expansion Continues with Singapore Application
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Orthocell
- Successful OrthoATI clinical trial
- UWA Royalty Entitlement Exchanged for Shares in Orthocell
- Striate re-certified under new European medical device regs
- Orthocell receives A$3.17m R&D tax incentive refund
- Orthocell commences nerve repair study
Later from Orthocell
- Strategic Placement to Raise $3.5 million
- Appendix 4D & Half-Year Financial Statements
- Part 1 Remplir US Market Authorisation Successfully Complete
- Orthocell receives $3.05m R&D tax incentive refund
- Outstanding 98.6% Success Rate in Striate Implant Study
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell